Ontology highlight
ABSTRACT:
SUBMITTER: Merryman RW
PROVIDER: S-EPMC6913426 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Merryman Reid W RW LaCasce Ann A
Hematology. American Society of Hematology. Education Program 20191201 1
The approval of brentuximab vedotin (BV) and the PD-1 inhibitors nivolumab and pembrolizumab has dramatically improved outcomes for patients with relapsed or refractory (R/R) classic Hodgkin lymphoma (HL). With the goal of increasing long-term disease control rates and decreasing late toxicities, these agents are currently being tested in earlier phases of treatment in combination with chemotherapy agents. In the R/R setting, our expanding understanding of HL's various mechanisms of immune evasi ...[more]